---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060462"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:48:40.581110+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed

## Summary
- Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.
- Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.
- Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).
- Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience.

## SEC filing metadata
- accession: 0000950170-24-060462
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/sndx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060462
- JSON: https://secwatch.observer/filing/0000950170-24-060462.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060462.txt

## Key facts
- Executive change
  Aleksandra Rizo was elected as Director at Syndax Pharmaceuticals Inc.
  - Action: elected
  - Role: Director
  source text: On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm
- Executive change
  Briggs W. Morrison resigned as Director at Syndax Pharmaceuticals Inc.
  - Action: resigned
  - Role: Director
  source text: On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm
- Shareholder Votes
  Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2024-05-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-15
  source text: Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Martin H. Huber, M.D. 61,876,711 736,625 3,032,770
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm
- Shareholder Votes
  Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-05-15
  source text: Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 46,228,421 16,304,796 80,119 3,032,770
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm
- Shareholder Votes
  Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2024-05-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-05-15
  source text: Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 65,371,337 253,270 21,499 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.